The goal of this study was to further explore potential mechanisms through which diabetogenic dietary conditions that result in promotion of insulin resistance (IR), a feature of non-insulin dependant diabetes mellitus (type-2 diabetes), may influence Alzheimer's disease (AD). Using genome-wide array technology, we found that connective tissue growth factor (CTGF), a gene product described previously for its involvement in diabetic fibrosis, is elevated in brain tissue in an established mouse model of diet-induced IR. With this evidence we continued to explore the regulation of CTGF in postmortem AD brain tissue and found that CTGF expression correlated with the progression of AD clinical dementia and amyloid neuritic plaque (NP) neuropathology, but not neurofibrillary tangle (NFT) deposition. Consistent with this evidence, we also found that exposure of Tg2576 mice (a model AD-type amyloid neuropathology) to a diabetogenic diet that promotes IR results in a ~2-fold elevation in CTGF steady-state levels in the brain, coincident with a commensurate promotion of AD-type amyloid plaque burden. Finally, using in vitro cellular models of amyloid precursor protein (APP)-processing and Aβ generation/clearance, we confirmed that human recombinant (hr)CTGF may increase Aβ 1-40 and Aβ 1-42 peptide steadystate levels, possibly through a mechanism that involves γ-secretase activation and decreased insulin-degrading enzyme (IDE) steady-state levels in a MAP kinase (MAPK)/ phosphatidylinositol 3-kinase (PI-3K)/protein kinase-B (AKT)1-dependent manner. The findings in this study tentatively suggest that increased CTGF expression in the brain might be a novel biological predicative factor of AD clinical progression and neuropathology in response to dietary regimens promoting IR conditions.
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ecent studies indicate that certain cardiovascular risk factors (CvRFs) may promote an increased risk of vascular-related dementia (VaD) (1, 2) . However, a large body of evidence indicates that CvRFs, such as dietary conditions promoting the development of insulin resistance (IR), may also increase the relative risk of Alzheimer's disease (AD) and clinical dementia even in the absence of VaD (3) (4) (5) (6) . Thus, it may be the case that additional "non-vascular" events associated with certain CvRFs (e.g., IR) may be responsible for this increased risk of AD.
For example, existing evidence suggests that insulin itself may significantly promote amyloidogenic Aβ peptide secretion through mechanisms involving acceleration of amyloid precursor protein (APP)/Aβ trafficking from the trans-Golgi network, a major cellular site for Aβ generation, to the plasma membrane (7) (8) (9) . Consistent with this evidence, recent epidemiologic studies indicate that hyperinsulinemic conditions associated with IR, and that are known to play a major role in VaD (10) (11) (12) , are strongly associated with an increased risk of AD and a decline in memory function (13, 14) . Further, activation of insulin receptor signaling pathways, such as PI-3K/AKT1 in the brain, may promote AD amyloidogenesis (9, 15, 16) . While this evidence supports the hypothesis that IR may be an underlying condition responsible for increased relative risk of AD, it is not known whether "non-vascular" events in the brain associated with CvRFs influence AD neuropathology and progression.
In the present study we identified novel molecular indices of IR in the brain using genome-wide array studies, after which we characterized their predicative role in the progression of AD clinical dementia and neuropathology. We report that the expression of connective tissue growth factor (CTGF), a gene product involved in diabetic fibrosis in peripheral organs (17, 18) , is elevated in the brain of patients with AD and correlated with the progression of AD clinical dementia and neuritic plaque (NP) neuropathology, but not neurofibrillary tangle (NFT) deposition. Consistent with this evidence, we also found that an IR-promoting diabetogenic diet coincides with ~2-fold elevation in CTGF steady-state levels. Additionally, administration of this diet also was found to increase AD-type amyloid plaque burden in a mouse model of AD-type neuropathology, thus confirming a role for CTGF in promoting Aβ amyloidogenesis in vitro. Collectively, the findings in this study suggest that CvRFs (e.g., IR) associated with VaD may independently contribute to development and progression of AD through the promotion of amyloid neuropathology.
MATERIALS AND METHODS

Brain gene expression profiling in a mouse model of IR
For the characterization of IR responding genes in the brain by cDNA microarray, we adopted an established mouse model in which IR (19) is promoted by exposing ~5-month-old 129/svJ male mice (Jackson Lab, Bar Harbor, ME) to a ~6-month-long diabetogenic diet with a macronutrient caloric composition composed of 60% fat (from lard), 20% simple carbohydrate (sucrose and maltodextrine), and 20% protein (Research Diets, Inc., New Brunswick, NJ; Product #D12450B) (20) . Control mice were maintained on a standard rodent diet, which contained less saturated fat (~13% energy from fat), more complex carbohydrates (~60% starch), and 20% protein. Both diets contained a standard vitamin and mineral mix with all essential nutrients, and a cholesterol content within the range of that reported for most mice vivaria diets (21) . Access to chow and drinking water was ad libitum in both groups as described previously (15) . The Institutional Animal Care Committee of The Mount Sinai School of Medicine reviewed and approved all experimental protocols used in this study.
Abnormal metabolic responses associated with diet-induced IR were assessed by intraperitoneal glucose tolerance testing (IGTT) as described previously (15, 15, 22) . Briefly, following an overnight fast, mice were given a single dose of glucose (2 g/kg body weight) administered intraperitoneally; tail vein blood samples were collected periodically over a 2 h period, from which blood glucose content was determined directly using a commercial blood glucose monitoring system according to manufacturer's instructions (OneTouch LifeScan System, LifeScan, Milpitas, CA). Serum insulin was measured using a commercial rat insulin ELISA kit (Crystal Chem Inc., Downers Grove, IL) according to manufacturer's instructions.
Two weeks after the IGTT, the mice were anesthetized with 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether (isoflurane; Baxter Healthcare Corp., Deerfield, IL) and killed by cervical dislocation. Brain tissue was microdissected, rapidly frozen, pulverized in liquid nitrogen, and stored at -80°C for subsequent RNA extraction using the Oligotex mRNA Mini Kit (Qiagen, Valencia, CA) as described previously (15, 15, 23) . For the gene expression profile studies, we used an oligonucleotide DNA microarray (CodeLink systems, Motorola) containing 10,013 genes (24, 25) . Cerebral cortical tissue from each mouse was analyzed in duplicate microarrays (n=6 animals per group). Hybridization signals were subtracted from the local background, normalized by the median signal intensity of the entire slide, and analyzed for statistical differences between groups using the Cyber-T software package (for more information see: http://genomics.biochem.uci.edu/genex/cybert/). This analysis uses algorithms that apply a Bayesian statistic to improve the estimation of variance among datasets derived from low numbers of replicate samples, such as those typically encountered in microarray experiments. Results from the application of Bayesian statistics are incorporated into t test analysis to provide a more stringent test of statistical significance; a P value ≤0.05 was used for the Bonferroni's correction parameter in this study.
Human and mouse detection CTGF mRNA expression by RT-PCR assay
Quantitative human or mouse CTGF real-time (RT)-PCR was conducted as described previously, with minor modifications (26) . Briefly, total RNA was extracted from frozen brain tissue samples (Qiagen, Valencia, CA) and transcribed into cDNA by 40 rounds of PCR amplification in the presence of SYBR Green I (Molecular Probes, Eugene, OR), mouse CTGF primers (forward primer: 5′-AGC CTC AAA CTC CAA ACA CC-3′ and reverse primer: 5′-CAA CAG GGA TTT GAC CAC-3′) and human CTGF primers (forward primer: 5′-TTG GCA GGC TGA TTT CTA GG-3′ and reverse primer: 5′-GGT GCA AAC ATG TAA CTT TTG G-3′) using an ABI 7900HT thermal cycler (Applied Biosystems, Foster City, CA) at 95°C for 15 s (denaturation), 55°C for 15 s (annealing), and 72°C for 30 s (extension).
Amplicon size and reaction specificity was confirmed by agarose gel electrophoresis. CTGF RT-PCR amplification was monitored in real time following each thermal cycle by measurements of fluorescent emission generated by incorporation of SYBR Green into double-stranded DNA.
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Data were transformed into a semi-log plot where the x-axis represents PCR cycle number and the y-axis represents the log value of florescent intensity. For each reaction, the threshold cycle (C T ) (the number of PCR cycles corresponding to the detection threshold) was obtained. The copy number of the targeted gene in each sample was interpolated from its median C T value using a standard curve derived from parallel quantitative RT-PCR amplification of purified CTGF PCR product.
Postmortem AD brain
Human postmortem brain tissue samples from age-matched patients with or without AD were obtained from the Alzheimer's Disease Brain Bank of the Mount Sinai School of Medicine. The patients selected had exhibited either no significant neuropathologic features or exhibited only neuropathologic features associated with AD (27) . A multistep approach based on cognitive and functional status during the last 6 months of life was applied to the assignment of clinical dementia ratings (CDRs) as previously reported (28) . Samples of entorhinal cortex (EC) BM36/38 (postmortem intervals: 191-537 min) were divided into groups on the basis of patients' CDRs as follows: CDR 0, non-demented (n=13); CDR 0.5, mild cognitive impairment (MCI) (n=8); CDR 2, moderate AD dementia (n=14); and CDR 5, severe AD dementia (n=6).
The extent of Aβ NP and NFT staining in the EC-BM36/38 was assessed in accordance with the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropathologic battery (29) . Multiple (~5) high-power (×200, 0.5 mm 2 ) fields were examined in each histologic slide from multiple regions of tissue, according to the CERAD regional sampling scheme. The density of NPs and NFTs was rated on a 4-point scale as follows: 0, absent; 1, sparse; 3, moderate; and 5, severe. Plaques were visualized after either Bielschowsky silver or thioflavin-S staining. Three of the investigators were blinded to the clinical diagnosis of each patient until all quantitative analyses were complete and values were assigned to each specimen.
Promotion of IR in Tg2576 mice
To assess the role of IR in CTGF expression, and its relationship with AD-type neuropathology, ~3-month-old female Tg2576 mice (Taconic, Germantown, NY), a transgenic line that expresses human amyloid precursor protein with a familial APP(K670N,M671L) mutation, were exposed to either a diabetogenic or standard rodent laboratory diet for ~6 months, as described previously in our laboratory (15) . Promotion of IR was assessed by IGTT two weeks prior to sacrifice using the same procedures described above. As indicated, mice were anesthetized with 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether (isoflurane; Baxter Healthcare Corp., Deerfield, IL) and killed by cervical dislocation with the brain collected and hemi-dissected. One hemisphere was immersion-fixed overnight in 4% paraformaldehyde (PFA) for histologic/morphologic studies, while the other was dissected. Brain regions from the dissected hemisphere were rapidly frozen, pulverized in liquid nitrogen, and stored at -80°C for subsequent biochemical studies.
Stereologic assessment of AD-type amyloid neuropathology in Tg2576 mice
Freshly harvested mouse brain hemispheres were immersion-fixed overnight in 4% paraformaldehyde (PFA), then sectioned in the coronal plane on a Vibratome at a nominal thickness of 40 µm. From a random starting point, every 20th section was selected, and stained with monoclonal 6E10 antibody as described in Xiang et al. (30) . Mounted tissue sections were incubated in 70% formic acid for 10 min, rinsed in phosphate-buffered saline (PBS), and incubated in 0.3% (v/v) H 2 O 2 for 15 min to block endogenous peroxidase activity. After permeabilization with 0.2% (v/v) Triton X-100 in PBS, sections were incubated overnight with biotinylated mouse anti-Aβ (6E10; dilution 1:500; Senetek, St. Louis, MO) at 4°C in the presence of 1% (v/v) rabbit serum to reduce non-specific antibody binding. Immunostaining was visualized using Vectastain ABC and DAB kits (Vector Laboratories, Burlingame, CA).
Sections adjacent to those used for 6E10 immunostaining were stained with cresyl violet to clarify the cytoarchitecture. This resulted in 2 adjacent series of 14 evenly spaced sections each. All stereologic analyses were performed using a Zeiss Axiophot photomicroscope equipped with a Zeiss motorized stage and MSP65 stage controller, a high-resolution Zeiss ZVS-47E digital camera, and a Macintosh G3 computer running the custom-designed software NeuroZoom (31) (32) (33) . Every other section from the Nissl-stained series was used to estimate the total volume of the cerebral cortex (i.e., neocortex and hippocampus) with the Cavalieri principle and a 200 × 200 µm counting grid. The amyloid burden was estimated using the Cavalieri principle and a smaller size grid (50×50 µm) according the method described by Bussière et al. (34) . This provides an unbiased estimate of the fractional volume of the region of interest that is occupied by amyloid. The burden percentage can then be calculated from the cerebral cortical volume itself. The number of amyloid plaques was estimated from the 6E10-labeled series by counting systematically all the 6E10-immunopositive plaques present in the cerebral cortex at low magnification (×10). Estimates of plaque volume were obtained using a systematic random sampling procedure at intermediate magnification (×40) (35) . About 150 plaques were analyzed in either group of mice. Amyloid plaque burden was calculated as amyloid plaque volume as percentage of cerebral cortical volume. 
Assessment of Aβ peptides in vivo and in vitro
Assessment of CTGF protein in postmortem human or Tg2576 brain samples
For Western blot protein expression studies, parallel aliquots of frozen postmortem human or mouse brain tissue samples used for RT-PCR studies, respectively, were lysed in RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease inhibitors. Lysates were then centrifuged (10,000 × g for 10 min) and supernatants collected for protein content determination by the Bradford method (Bio-Rad, Laboratories, Hercules, CA). Proteins were resolved electrophoretically by SDS-PAGE, transferred to Immobilon-P transfer membranes (Millipore Corporate, Billerica, MA) and immunoprobed with polyclonal anti-CTGF antibodies (1:5,000, Abcam Lt. Cambridge, MA), polyclonal anti-p42/44 MAPK (1:1000, Biosource, Camarillo, CA), anti-phospho MAP kinase (pTpY Louis, MO) or anti-phospho AKT (pS 473 -AKT, 1:1000, Cell Signaling, Beverly, MA). To control for protein loading or selectivity of changes, membranes were stripped and reacted with β-actin immunoreactivity (1:3,000 dilution, Sigma). Immunoreactivities were visualized by fluorescence autoradiography using ECL Plus TM enhanced chemiluminescence detection (Super Signal detection kit, Pierce, Rockford, IL) and quantified densitometrically.
In vitro cell cultures
H4-(APP) 751 neuronal cells (gift from Dr. Buxbaum) were generated by stable transfection of H4 neuronal cells with pCMV-(APP) 751 and pBABE, and they were maintained in DMEM with 10% fetal bovine serum, 100 U/ml penicillin/streptomycin, 1 µg/ml tetracycline, 200 µg/ml G418, 150 µg/ml hygromycin, and 1 µg/ml puromycin. The cells were then seeded at 3 × 10 4 cells/cm 2 , and cultured at 37°C in the presence of 5% CO 2 for 24 h (60% confluence in 6-well dishes). For treatment studies, H4-(APP) 751 neuronal cultures were pre-incubated with serum-free DMEM medium containing PD98059 (10 μM, Calbiochem, San Diego, CA) or Wortmannin (1 μM, Sigma, St. Louis, MO), from 5 mM DMSO stocks stored at -20°C, for 30 min followed by treatment with human recombinant (hr)CTGF (diluted from 1 μM stock in PBS), at -37°C for 24 h (36, 37). At each time indicated, for collection of conditioned media and cell lysates, tissue culture dishes were placed on ice (4°C). After removal of media, cell lysates were immediately collected in ice in 1× SDS-PAGE containing protease inhibitors.
Assessment of γ-secretase activity
The γ-secretase activity assay was based on assessing the generation of the ~7 kDa carboxyl terminal fragment (CTF)-γ cleavage product from membrane-associated APP using a described previously method, with minor modifications (15, 38) . Briefly, H4-(APP) 751 cells were washed once and scraped down in cold PBS. After centrifugation (1,500 rpm, 10 min at 4°C), cells were lysed in homogenization buffer (10 mM MOPS pH 7.0, 10 mM KCl, 1× Complete Protease Inhibitor Cocktail) by passing the cell suspension through a 23-gauge needle 15 times. The homogenates were centrifuged (2,500 rpm, 15 min at 4°C) to remove nuclei and cell debris. The supernatant (membrane and postnuclear supernatant) was then centrifuged (14,000 rpm, 20 min, 4°C) and rinsed in homogenization buffer.
Membrane preparations (200 µg protein) were resuspended in 50µl assay buffer (150 mM sodium citrate pH 6.4; 1× Complete Protease Inhibitor Cocktail). Half the samples were incubated for 2 h at 37°C to generate the CTF-γ cleavage product, while the other half was maintained on ice as negative controls. CTF-γ cleavage products (as well as CTF-α and CTF-β) were resolved electrophoretically in 10-20% Tris-Tricine gels (Bio-Rad Laboratories), and identified using an anti-APP polyclonal C8 antibody (gift from Dr. Dennis Selkoe; 1:500 dilution). Immunoreactivities were visualized autoradiographically using a chemiluminescence detection kit (SuperSignal; Pierce Biotechnology, Rockford, IL).
Insulin-degrading enzyme (IDE) expression and activity
IDE content was assessed in the same membrane preparations used for assessment of γ-secretase activity in H4-(APP) 751 . Membrane-associated IDE expression was assessed by Western blot analysis using anti-IDE antibodies (clone BC2 1:500 dilutions, gift from Dr. Eduardo Castano).
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Analysis of membrane-associated IDE activity was based on degradation of 125 I-insulin as described previously (39) . Briefly, membrane preparations were incubated in the presence of 125 I-insulin for the period of time indicated, followed by TCA precipitation. Measurement of 125 Iinsulin released into the TCA-soluble fraction represents degraded insulin and directly reflects IDE activity.
Statistics
All values are expressed as mean ± SEM. Differences among mean values were analyzed using two-way ANOVA, while differences between means were assessed by two-tailed Student t tests or Dunnett's post-hoc tests as indicated in the text below. In all analyses, the null hypothesis was calculated by the Prism Stat software program (GraphPad Software, Inc., San Diego CA) and rejected at the 0.05 level.
RESULTS
Brain gene expression profiling in response to dietary conditions promoting IR in 129/svJ mice
The goal of this study was to identify potential novel gene products whose expression in the brain is influenced in ~9 month-old 129/svJ mice following ~6 months' exposure to an established diabetogenic diet, resulting in the promotion of IR (19) . Abnormal glucose metabolic changes in mice fed the diabetogenic diet were assessed by IGTT 2 weeks prior to sacrifice. This assessment showed that IR mice had significantly higher levels of plasma insulin (Fig. 1A) and plasma glucose (Fig. 1B) for a longer duration of time, compared with control normoglycemic mice fed a standard rodent laboratory diet, following glucose administration.
Consistent with this evidence, we found >1.5-fold elevation in increased body weight and ependymal fat pad weight in IR mice, relative to control normoglycemic mice fed a standard rodent laboratory diet (not shown). Using this evidence, we continued to survey for potential changes in gene expression associated with the promotion of IR in the brain using highthroughput cDNA microarray technology.
We identified 36 known genes and 12 expressed sequence tags (EST) differentially regulated by ≥1.7-fold (Student's t test P<0.0001) in the cerebral cortex in response to dietary conditions resulting in IR, compared with control normoglycemic mice (Pasinetti, unpublished observation). Importantly, we found that steady-state levels of CTGF mRNA, a gene product previously implicated in the pathophysiology of diabetes (40) (41) (42) , were elevated in the brains of IR mice compared with normoglycemic mice fed a standard rodent laboratory diet.
Following RT-PCR assays confirming that CTGF steady-state levels are elevated at the mRNA (Fig. 1C) and protein (Fig. 1D ) levels in the cerebral cortex of IR mice, we continued to explore the potential relationship between this novel predicative index of IR in the brain and AD dementia and neuropathology.
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CTGF expression is increased in the AD brain as a function of clinical AD dementia and Aβ neuritic plaques, but not neurofibrillary tangle pathology
Patient demographic information pertaining to samples of the EC BM36/38 included in this study is summarized in Table 1 describing different CDR groups with respect to postmortem interval and age at death. Cause of death was reviewed for all patients to rule out the possibility that intercurrent infection or other events could affect study measures.
We found a significant and progressive elevation of CTGF protein ( Fig. 2A) concentrations in the EC BM36/38 of patients demonstrating MCI (CDR 0.5) to moderate dementia (CDR 2) and severe dementia (CDR 5), compared with patients with normal cognitive status (CDR 0). Similarly, we found that among all individual cases, expression of CTGF in the EC positively correlated with total cortical Aβ 1-42 content (r 2 =0.58, P<0.01; Fig. 2B ). Consistent with this observation, we also found that the overall elevation of CTGF expression in the EC increased as a function of NP (P<0.05) (Fig. 2C ), but not NFT formation (Fig. 2D ) based on CERAD scores for AD neuropathology (43) .
In parallel immunocytochemical (ICC) studies, we continued to explore the regional distribution and cell type expression of CTGF in the brain as a function of CDR. Consistent with recent ICC evidence (44), we found an apparent consistent elevation of immunodetectable CTGF signal in neuronal cells of the hippocampal CA1-CA3 pyramidal layer (not shown). Interestingly, we also found strong CTGF immunoreactivity associated with amyloid plaque deposits, a finding consistent with the hypothesis that CTGF may be a secreted protein in the brain (as in peripheral organs).
With this evidence, we continued to explore the potential interrelationship between CTGF expression and AD-type amyloid neuropathology in Tg2576 mice in response to dietary conditions promoting IR.
CTGF expression is selectively elevated in the brain of IR Tg2576 mice coincident with increased Aβ neuropathology
In initial control studies we examined the regulation of CTGF steady-state levels in the brain of Tg2576 mice relative to wild-type (WT) control mice fed standard rodent laboratory diet. We found that under this dietary regimen, CTGF protein concentrations in the cerebral cortex of ~9-month-old Tg2576 mice did not differ from that found in strain-, age-, and gender-matched WT control littermates (Fig. 3A) fed the same diet. This observation is consistent with evidence showing no detectable alterations in baseline glucose utilization assessed by IGTT assay between the Tg2576 and WT fed the same standard laboratory diet (Fig. 3B) We found that exposure of Tg2576 mice for 6 months to a high-fat diabetogenic diet resulting in the promotion of IR coincided with a ~1.5-fold elevation in cortical CTGF protein concentration in ~9-month-old Tg2576 mice, relative to normoglycemic Tg2576 mice fed a standard rodent =0 .0014 for interaction) (Fig. 3D) following exposure to the diabetogenic diet, relative to age-gender matched normoglycemic control Tg2576 mice. We also noted a >2.5-fold elevation in circulating serum insulin content and increased body weight in IR Tg2576 mice relative to control normoglycemic Tg2576 mice fed a standard laboratory diet (data not shown). Based upon this evidence, we next explored the association between CTGF steady-state levels and AD-type amyloid neuropathology in the cerebral cortrex of IR Tg2576 mice.
We found that dietary conditions promoting IR and elevated CTGF expression in the brain coincided with a >twofold elevation in steady-state levels of amyloidogenic Aβ 1-40 and Aβ peptides in the cerebral cortex relative to normoglycemic Tg2576 control mice (P<0.05) (Fig.  3E) . Consistent with this evidence we found a ~2-fold increase in cerebral cortical AD-type amyloid (6E10-immunopositive) plaque burden (plaque volume as percentage of the total cerebral cortical volume; P<0.05) (Fig. 3F ), relative to control normoglycemic Tg2576 mice. No detectable alteration in 22C11-immunoreactive total holo-APP steady-state level was noted in the cerebral cortex of IR Tg2576 mice relative to normoglycemic Tg2576 mice (not shown).
With this evidence we continued to explore the potential causal role of human recombinant (hr)CTGF in mechanisms associated with Aβ amyloid generation/degradation in H4-(APP) 751 cultures. Treatment of cultures with exogenous hrCTGF (2.5 nM) was found to result in a ~2-fold elevation (P<0.01) in the steady-state levels of Aβ and Aβ 1-42 peptides in conditioned media (Fig. 4A) . This elevation was coincident with increased generation of the ~7 kDa CTF-γ processed form of APP, normalized to total holo-APP concentrations (see Fig. 4B , inset) in the in H4-(APP) 751 membrane fraction (P<0.05), an index of γ-secretase activity, relative to vehicle treated cultures, 24 h after treatment (Fig. 4B) . No detectable change in the generation of the CTF-α was found (Fig. 4B) . Compared with the CTF-α (or CTF-γ) fragments, the abundance of CTF-β signal was at or below the limit of detection of H4-(APP) 751 , preventing reliable quantification.
No detectable change in total membrane-bound holo-APP steady-state levels by hrCTGF treatment was found (Fig. 4B, inset) , suggesting that hrCTGF may influence APP processing without influencing APP steady-state levels.
hrCTGF negatively influences IDE steady-state levels H4-(APP) 751 IDE, originally recognized for its role in degrading insulin, has recently received attention for its potential role as an "amyloidase" integral to the clearance of monomeric Aβ peptides (45) (46) (47) ). Thus, we tested the hypothesis that hrCTGF might also influence amyloidosis through modulation of IDE expression. In parallel studies using membrane fractions from neuronal H4-
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(APP) 751 cells used in the assessment of the CTF-γ processed form of APP, we found ~1-fold decreased steady-state levels of IDE protein content normalized to total holo-APP concentrations (Fig. 4C) , relative to vehicle-treated cells (P<0.02). Thus, while hrCTGF may influence the Aβ synthetic pathway through promotion of γ-secretase activity, hrCTGF may also promote Aβ peptide content in conditioned media in response to decreased IDE expression. Consistent with this hypothesis, we found that treatment of H4-(APP) 751 with hrCTGF results in decreased IDE enzymatic activity assessed by degradation of I 125 -radiolabeled insulin (data not shown). However, we cannot role out the possibility that the observed activity change was, in part, due to neprilysin and other metalloprotease activity as previously suggested (48) .
hrCTGF influences Aβ steady-state levels through mechanisms that involve p42/44 MAPK (ERK1/2) and PI3K-AKT1 signaling
Considering previous evidence suggesting that CTGF may influence extracellular matrix protein in mesangial cells through mechanisms partly involving MAPK (ERK1/2) and PI3K/AKT1 signaling (49, 50), we continued to explore these signaling pathways in relation to γ-secretase activity and IDE expression in H4-(APP) 751 cells.
In initial studies, we found that treatment of H4-(APP) 751 p44 MAPK and pS 473 -AKT1 gradually returned toward control levels by 120 min post-treatment. No detectable change in total p42/44MAPK,AKT1, or control actin concentrations were found at any time examined after hrCTGF treatment (Fig. 5E ).
We then investigated whether the changes in γ-secretase activity, IDE and Aβ steady-state levels in H4-(APP) 751 cells treated by hrCTGF were affected by signaling via p42/44 MAPK or PI3K/AKT1 pathways. Cells were pre-incubated with PD98059 (10 μM) or Wortmannin (1 μM), both of which are selective inhibitors of p42/44 MAPK or PI3K upstream of AKT1, respectively, for 30 min and then stimulated with hrCTGF for 24 h. We found that both PD98059 and Wortmannin prevented hrCTGF mediated changes in γ-secretase activity (Fig. 6A) , IDE steadystate levels (Fig. 6B ) in H4-(APP) 751 neuronal membrane-preparations, and Aβ state levels in conditioned media (Fig. 6C) . Treatment with Wortmannin alone, but not PD98059, caused a significant reduction in Aβ production in the conditioned medium, and also reduced γ-secretase activity and IDE steady-state levels in the cell membrane-preparations (data not shown).
DISCUSSION
In this study we found that AD clinical dementia and NP neuropathology, but not NFT deposition, positively correlated with CTGF protein concentrations in the brain, a finding also seen in the brain of IR Tg2576 mice. These findings tentatively suggest that increased CTGF expression in the brain may be a novel biological predicative factor influencing AD onset and clinical progression through the promotion of amyloid neuropathology in response to CvRFs such as IR-producing dietary regimens. This hypothesis is supported by the finding that hrCTGF may promote elevated steady-state levels of amyloidogenic Aβ peptides possibly through promotion of γ-secretase activity, responsible for the cleavage of APP at both Aβ1-40 and 1-42 cleavage sites, but also through changes in steady-state levels of IDE in H4-APP 751 neuronal cells (see Figure 7) .
In this study, we found elevated CTGF content in the AD brain, which selectively correlated with NP-amyloid neuropathology and clinical dementia. Although little is known about the underlying causes leading to CTGF induction in AD, our study for the first time suggests that CTGF expression could ultimately promote β-amyloidosis. Thus, we propose that increased CTGF expression in the AD brain may be a causative factor promoting amyloid neuropathology. Interestingly, we found that CTGF expression in the brain is also induced by dietary conditions leading to IR. While this condition is a common recurrent feature in the elderly population at high risk for AD, we are aware that not all AD patients may necessarily exhibit IR. Nonetheless, in view of the evidence that IR is one of the major risk factors for AD (1, 2), our study suggests that IR may exacerbate AD, in part, through promotion of CTGF-mediated responses. Given the dire need to understand early pathogenic mechanisms in AD, and to identify target populations for preventative interventions in respect to CvRFs such as dietary condition promoting IR, our study provides for the first time a novel biological framework for exploring IR as a predicative factor for AD.
CTGF, also known as insulin growth factor (IGF) binding protein (IGFBP-rP2) (51, 52) , is known to be up-regulated in the peripheral organs by experimental diabetes and hyperglycemia (53, 54) . It has also been implicated in mechanisms involved in the expansion of extracellular matrix in diabetes (51, 52) . Clearly CTGF has received a great deal of attention, primarily for its role in adaptive conditions in response to hyperinsulinemia leading to IR (52) (53) (54) (55) . Our study suggesting that hrCTGF may promote generation and/or decrease clearance of amyloidogenic Aβ peptides extends this evidence and suggests that CTGF may be a downstream effector of conditions promoting IR in AD and may therefore represent a novel suitable target for amyloidlowering therapeutic strategies in AD (56) .
Little is known about the CTGF receptor(s), and most of its activities have been ascribed to its binding to integrin cell surface receptors (49) , which can mediate a vast array of cellular processes, including cell adhesion and cell survival. In particular, recent studies indicate that CTGF may exert its biological activities in human mesangial cells through its binding to β3 intergrin receptor and eventual activation of signal transduction pathways. These activities are thought to take place through recruitment of the Src family of tyrosine kinases, and also through the activation of p42/44 MAPK and PI3K/AKT1 pathways (49) . Consistent with this evidence, we found that hrCTGF also activates p42/44 MAPK and PI3K/AKT1 pathways in human H4-APP 751 neuronal cells. These findings are of high interest because activation of MAPK pathways are directly involved in the generation of amyloidogenic Aβ peptides through promotion of the endocytic pathway of βAPP (9, 57) . Similarly, we note that PI3K/AKT1 is an upstream signaling pathway contributing to IDE up-regulation by insulin, indicating a cause-effect relationship between insulin signaling and IDE regulation (47) .
We also note that recent evidence indicates that the low-density lipoprotein receptor-related protein (LRP-RP) may also be a receptor for CTGF (58, 59) . This is highly relevant to understanding CTGF's role in AD because LRP can control both the generation and clearance of Aβ in the brain. This consideration, in concert with our evidence showing a potential causal (paracrine-mediated) role for hrCTGF in γ-secretase activity and inhibition of IDE expression in H4-APP 751 neuronal cells, which are known to also express LRP receptor, is consistent with the possibility that CTGF may mediate its effects through the LRP-RP receptor complex, ultimately influencing Aβ generation/clearance. Finally, we want to point out that cholesterol-lowering agents, in particular HMG-CoA reductase inhibitors, may inhibit CTGF expression in vitro, possibly through mechanisms involving isoprenylation of Rho proteins (60) . Thus, this last novel mode of action might also provide some explanation for the protective action of statins against certain CvRFs, which apparently does not strictly coincide with their cholesterol-lowering effects (60).
In conclusion, our study suggests that potential risk factors such as IR, which are accepted as CvRFs for vascular dementia, may also independently contribute to the development and progression of AD amyloid neuropathology. Further characterization of CTGF's role in AD and AD model systems will provide critical direction for future studies investigating mechanisms involved in the potentiation of AD neuropathology and cognitive impairment in the context of IR. 
